Singlepoint Healthcare, a specialty care company for people living with inflammatory disease, is planning to make three to five acquisitions by the end of 2026, CEO Chuck Jett said.

Backed by DFW Capital Partners, Singlepoint is working to build a multi-specialty network that integrates neurology, rheumatology, and immunology with ancillary services such as infusion, specialty pharmacy, imaging, rehabilitation, nutrition and behavioral health, to provide care through a single point of access, the CEO explained.

Attractive acquisition candidates include neurology practices treating 750 to 1,000 patients with multiple sclerosis, located in the eastern half of the country and in the Midwest, Jett said.

Singlepoint has a pipeline of candidates on its radar and is in talks with some of them, he said. It has an internal M&A team and receives inbound offers from advisors, he said. The objective is to acquire 100% of the target, he added.

There are not many companies for sale in the space, Jett said. He explained that Singlepoint directly seeks potential acquisition candidates and starts building a relationship with them. He noted that the transaction prices in this sector are usually based on single-digit EBITDA multiples.

Deals will be financed with the support of DFW Capital Partners, Jett said.

Founded this year, Singlepoint aims to expand into eight to 10 markets through acquisitions in the next three years, the CEO said. He explained that it is looking at 20 markets at this point, but did not elaborate further.

The objective is to grow the current undisclosed revenue figure to USD 350m-USD 500m in three years, he said. The company is profitable, he added.

There are no other companies with the same offering as Singlepoint at the moment, the other players in the space often provide only some of the services, Jett said, discussing the competitive landscape.

Earlier this month Singlepoint announced the acquisition of IV Solutions, a provider of clinical pharmacy and home infusion services located in Wood Dale, Illinois. The company’s first deal was the acquisition of The Boster Center for Multiple Sclerosis, a multiple sclerosis practice in Colombus Ohio, which was announced in July.

Jett has decades of experience leading healthcare and technology-enabled service organizations. From 2020 to 2024 he was CEO at Infusion Associates, which was acquired by Vivo Infusion in July 2024.